Alteration of osteoclast activity in childhood cancer survivors: Role of iron and of CB2/TRPV1 receptors.
Childhood cancer survivors (CCS) are predisposed to the onset of osteoporosis (OP). It is known that iron overload induces osteoclasts (OCs) overactivity and that the iron chelator Deferasirox (DFX) can counteract it. The Cannabinoid Receptor type 2 (CB2) and the transient receptor potential vanillo...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2022-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0271730 |
| _version_ | 1811222368383664128 |
|---|---|
| author | Francesca Rossi Chiara Tortora Martina Di Martino Alessandra Di Paola Daniela Di Pinto Maria Maddalena Marrapodi Maura Argenziano Elvira Pota |
| author_facet | Francesca Rossi Chiara Tortora Martina Di Martino Alessandra Di Paola Daniela Di Pinto Maria Maddalena Marrapodi Maura Argenziano Elvira Pota |
| author_sort | Francesca Rossi |
| collection | DOAJ |
| description | Childhood cancer survivors (CCS) are predisposed to the onset of osteoporosis (OP). It is known that iron overload induces osteoclasts (OCs) overactivity and that the iron chelator Deferasirox (DFX) can counteract it. The Cannabinoid Receptor type 2 (CB2) and the transient receptor potential vanilloid type-1 (TRPV1) are potential therapeutic targets for OP. In this study we isolated OCs from peripheral blood of 20 CCS and investigated osteoclast biomarkers expression and iron metabolism evaluating iron release by OCs and the expression of several molecules involved in its regulation. Moreover, we analyzed the effects of CB2 and TRPV1 stimulation in combination with DFX on osteoclast activity and iron metabolism. We observed, for the first time, an osteoclast hyperactivation in CCS suggesting a role for iron in its development. Moreover, we confirmed the well-known role of CB2 and TRPV1 receptors in bone metabolism, suggesting the receptors as possible key biomarkers of bone damage. Moreover, we demonstrated a promising synergism between pharmacological compounds, stimulating CB2 or inhibiting/desensitizing TRPV1 and DFX, in counteracting osteoclast overactivity in CCS to improve their quality of life. |
| first_indexed | 2024-04-12T08:15:46Z |
| format | Article |
| id | doaj.art-9ab5297887194275a4ecb6d2e056c30e |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-04-12T08:15:46Z |
| publishDate | 2022-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-9ab5297887194275a4ecb6d2e056c30e2022-12-22T03:40:49ZengPublic Library of Science (PLoS)PLoS ONE1932-62032022-01-01177e027173010.1371/journal.pone.0271730Alteration of osteoclast activity in childhood cancer survivors: Role of iron and of CB2/TRPV1 receptors.Francesca RossiChiara TortoraMartina Di MartinoAlessandra Di PaolaDaniela Di PintoMaria Maddalena MarrapodiMaura ArgenzianoElvira PotaChildhood cancer survivors (CCS) are predisposed to the onset of osteoporosis (OP). It is known that iron overload induces osteoclasts (OCs) overactivity and that the iron chelator Deferasirox (DFX) can counteract it. The Cannabinoid Receptor type 2 (CB2) and the transient receptor potential vanilloid type-1 (TRPV1) are potential therapeutic targets for OP. In this study we isolated OCs from peripheral blood of 20 CCS and investigated osteoclast biomarkers expression and iron metabolism evaluating iron release by OCs and the expression of several molecules involved in its regulation. Moreover, we analyzed the effects of CB2 and TRPV1 stimulation in combination with DFX on osteoclast activity and iron metabolism. We observed, for the first time, an osteoclast hyperactivation in CCS suggesting a role for iron in its development. Moreover, we confirmed the well-known role of CB2 and TRPV1 receptors in bone metabolism, suggesting the receptors as possible key biomarkers of bone damage. Moreover, we demonstrated a promising synergism between pharmacological compounds, stimulating CB2 or inhibiting/desensitizing TRPV1 and DFX, in counteracting osteoclast overactivity in CCS to improve their quality of life.https://doi.org/10.1371/journal.pone.0271730 |
| spellingShingle | Francesca Rossi Chiara Tortora Martina Di Martino Alessandra Di Paola Daniela Di Pinto Maria Maddalena Marrapodi Maura Argenziano Elvira Pota Alteration of osteoclast activity in childhood cancer survivors: Role of iron and of CB2/TRPV1 receptors. PLoS ONE |
| title | Alteration of osteoclast activity in childhood cancer survivors: Role of iron and of CB2/TRPV1 receptors. |
| title_full | Alteration of osteoclast activity in childhood cancer survivors: Role of iron and of CB2/TRPV1 receptors. |
| title_fullStr | Alteration of osteoclast activity in childhood cancer survivors: Role of iron and of CB2/TRPV1 receptors. |
| title_full_unstemmed | Alteration of osteoclast activity in childhood cancer survivors: Role of iron and of CB2/TRPV1 receptors. |
| title_short | Alteration of osteoclast activity in childhood cancer survivors: Role of iron and of CB2/TRPV1 receptors. |
| title_sort | alteration of osteoclast activity in childhood cancer survivors role of iron and of cb2 trpv1 receptors |
| url | https://doi.org/10.1371/journal.pone.0271730 |
| work_keys_str_mv | AT francescarossi alterationofosteoclastactivityinchildhoodcancersurvivorsroleofironandofcb2trpv1receptors AT chiaratortora alterationofosteoclastactivityinchildhoodcancersurvivorsroleofironandofcb2trpv1receptors AT martinadimartino alterationofosteoclastactivityinchildhoodcancersurvivorsroleofironandofcb2trpv1receptors AT alessandradipaola alterationofosteoclastactivityinchildhoodcancersurvivorsroleofironandofcb2trpv1receptors AT danieladipinto alterationofosteoclastactivityinchildhoodcancersurvivorsroleofironandofcb2trpv1receptors AT mariamaddalenamarrapodi alterationofosteoclastactivityinchildhoodcancersurvivorsroleofironandofcb2trpv1receptors AT mauraargenziano alterationofosteoclastactivityinchildhoodcancersurvivorsroleofironandofcb2trpv1receptors AT elvirapota alterationofosteoclastactivityinchildhoodcancersurvivorsroleofironandofcb2trpv1receptors |